Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of Dipeptidyl Peptidase-IV Inhibition. Diabetes Care 2012;35:2076–2082

Diabetes Care, Feb 2014

Maria Rosaria Rizzo, Michelangela Barbieri, Raffaele Marfella, Giuseppe Paolisso

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

http://care.diabetesjournals.org/content/37/2/587.2.full.pdf

Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of Dipeptidyl Peptidase-IV Inhibition. Diabetes Care 2012;35:2076–2082

Glucose (mg/dL) Fasting 0 1 -h Postprandial MAGE manual (mg/dL) MAGE EasyGV (mg/dL) 0 1 0 Maria Rosaria Rizzo , Michelangela Barbieri, Raffaele Marfella, and Giuseppe Paolisso 1 In the article listed above, the source of funding for the study was not specified. The study was funded by an Institutional Grant of the Department of Medical , Surgical, Neurological , Metabolic and Aging Sciences, Second University of Naples Also, the MAGE data were manually calculated according to the method of Service et al., as reported on page 2077 of the article. Post hoc analysis of the original research data by automated algorithm EasyGV (EasyGV, Version 9.0, by Nathan R. Hill, www.easygv.co.uk) found differences in MAGE values obtained by the two different calculation methods, but confirmed that 1) vildagliptin significantly lowered MAGE and 2) vildagliptin had a stronger reduction in MAGE than sitagliptin. In addition, the EasyGV analysis showed that sitagliptin has a significant effect on MAGE reduction. The results of these analyses are reported in Tables A and B below. As expected, the EasyGV analyses of the data support the discussion of the results and confirm the conclusions reported in the article. - 146.41 6 6.31 216.83 6 7.23 70.80 6 21.58 85.88 6 21.15 After 12 weeks 114.65 6 6.81 169.20 6 5.41 64.75 6 11.39 74.37 6 14.36 147.80 6 6.81 215.66 6 7.36 73.93 6 18.39 81.08 6 15.83 After 12 weeks 116.05 6 5.15 169.38 6 5.00 45.35 6 5.95 51.02 6 7.65 Table BDifferences between treatments (after 12 weeks and baseline) Glucose (mg/dL) Fasting 2-h Postprandial MAGE manual (mg/dL) MAGE EasyGV (mg/dL) 231.76 6 7.68 2 47.63 6 9.2 26.05 6 24.3 211.51 6 25.25 231.74 6 8.55 246.28 6 9.94 228.58 6 18.92 230.06 6 17.79 Data are mean 6 SD unless otherwise indicated. **Independent t test. Sitagliptin and vildagliptin 2 3.42 to 3.39 25.37 to 2.66 13.4 to 31.67 9.39 to 27.7


This is a preview of a remote PDF: http://care.diabetesjournals.org/content/37/2/587.2.full.pdf

Maria Rosaria Rizzo, Michelangela Barbieri, Raffaele Marfella, Giuseppe Paolisso. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of Dipeptidyl Peptidase-IV Inhibition. Diabetes Care 2012;35:2076–2082, Diabetes Care, 2014, 587-588, DOI: 10.2337/dc14-er02a